2023 · European journal of drug metabolism and pharmacokinetics · paywalled
Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
de Klaver et al.
The finding, in our words
Early at-home VAMS samples allowed Bayesian forecasting of steady-state adalimumab concentrations with modest bias (mean prediction error -2.6%) and acceptable precision (normalised RMSE 24.0%), correctly classifying 75% of predictions within the therapeutic window and identifying 8.3% of patients who developed anti-adalimumab antibodies, supporting decentralised precision dosing during induction.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
When patiromer is taken three hours after tacrolimus, it does not alter tacrolimus exposure in kidney transplant recipients. The study also shows that self-collected capillary blood samples using volumetric absorptive microsampling (VAMS) can reliably measure tacrolimus concentrations, which simplifies pharmacokinetic studies and enables decentralised therapeutic drug monitoring.
The authors developed and validated a workflow that couples Mitra volumetric absorptive microsampling with hybridisation LC-MS/MS to quantify the antisense oligonucleotide fomivirsen in human blood. Quantitative recovery was achieved irrespective of haematocrit level or sample age, and the method demonstrated sensitivity, linearity, precision, accuracy, and four-month stability, supporting its use for therapeutic drug monitoring of biologic candidates in decentralised trials.
The study developed and validated a LC-MS/MS assay for imatinib and its metabolite using volumetric absorptive microsampling, enabling reliable home blood collection by patients with chronic myeloid leukaemia. Therapeutic drug concentrations measured from VAMS were comparable across adherence groups, supporting the use of VAMS for routine decentralised monitoring of imatinib therapy.